Drug Profile


Alternative Names: CL 273547; Ocinaplon sustained release

Latest Information Update: 15 Nov 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer DOV Bermuda; Wyeth
  • Class Anxiolytics; Pyrimidines; Small molecules
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Generalised anxiety disorder

Most Recent Events

  • 03 Nov 2005 Discontinued - Phase-III for Generalised anxiety disorder in USA (PO)
  • 25 Aug 2005 Suspended - Phase-III for Generalised anxiety disorder in USA (PO)
  • 25 Nov 2004 Phase-III clinical trials in Generalised anxiety disorder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top